Thyme Care raises $125 million, pushing cancer care startup's valuation above $2 billion

Thyme Care has raised $125 million from investors in a deal doubling the cancer startup's valuation as it tackles critical disease treatment gaps.

Original reporting by CNBC. GridIndex is an aggregation and intelligence layer — full credit to the original publisher.